Generic Manufacturers Try To Up Their Game As US Pressure Persists
Executive Summary
With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.
You may also be interested in...
After The Cliff: Fewer Patent Expiries Mean Less Savings From Generics
A PwC report on medical cost trends projects that while US health care cost-growth has plateaued, several inflationary factors remain, including a reduction in big-ticket prescription drugs going off-patent. The trend began in 2016 and is expected to continue in 2018.
Generic Industry Consolidating But Still Mysterious
Nearly 2,000 ANDAs remain unclaimed as US FDA begins fee calculations for GDUFA II.
Can US FDA Save Pharma From Price Controls?
FDA Commissioner Scott Gottlieb is making drug pricing a big theme of his first weeks as FDA commissioner. Will it be enough to head off other executive or legislative action on the issue?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: